TABLE 3

Summary of ADCs tested for rheumatic diseases that have entered clinical trials

ADCIndicationAntibodyLinkerPayloadTesting StatusThe Primary End PointReference
Anti–TNF-GRM ADC (ABBV-3373)Rheumatoid arthritisAnti-TNF mAb (adalimumab)Maleimide-Gly-Ala-Ala linkerGRMPhase IIa trial (NCT03823391)Change from baseline to week 12 in DAS 28 (CRP) (time frame: baseline and week 12)Buttgereit et al., 2023
Anti–TNF-GRM ADC (ABBV-154)Rheumatoid myalgiaAnti-TNF mAb (adalimumab)Maleimide-Gly-Ala-Ala linkerGRMPhase II trialTime to flare (time frame: up to week 52)NCT04972968
Anti–TNF-GRM ADC (ABBV-154)Crohn's diseaseAnti-TNF mAb (adalimumab)Maleimide-Gly-Ala-Ala linkerGRMPhase II trialPercentage of participants achieving endoscopic response per SES-CD (time frame: week 12 in the induction period)NCT05068284
Brentuximab vedotinSystemic lupus erythematosusAnti-CD30 mAb (brentuximab)Valine-citrulline linkerMMAEPhase II trial (NCT02533570)Number and percentage of subjects having an AE [time frame: up to 127 days (9 weeks after final dose)]Theocharopoulos et al., 2021
Brentuximab vedotinSystemic sclerosisAnti-CD30 mAb (brentuximab)Valine-citrulline linkerMMAEPhase II trialProportion of participants who experience at least one grade 3 or higher adverse event [time frame: from week 0 (≥ first dose of assigned treatment) to week 48 postrandomization]NCT03222492
Brentuximab vedotinSystemic sclerosisAnti-CD30 mAb (brentuximab)Valine-citrulline linkerMMAEPhase II trialChange in skin thickness measured by mRSS (time frame: 12 months)NCT03198689
Brentuximab vedotinSystemic sclerosisAnti-CD30 mAb (brentuximab)Valine-citrulline linkerMMAEPhase II trialChange in skin thickness measured mRSS (time frame: 48 weeks)NCT05149768
  • AE, adverse event; CRP, C-reative protein; DAS, Disease Activity Score; mRSS, modified Rodnan skin score; SES-CD, Simple Endoscopic Score for Crohn Disease.